HLA-C Antibody

Code CSB-PA320739LA01HU
Size US$166
Order now
Image
  • Western Blot
    Positive WB detected in: A549 whole cell lysate, Hela whole cell lysate, Mouse brain tissue
    All lanes: HLA-C antibody at 3.4µg/ml
    Secondary
    Goat polyclonal to rabbit IgG at 1/50000 dilution
    Predicted band size: 41 kDa
    Observed band size: 41 kDa

  • Immunohistochemistry of paraffin-embedded human lymph node tissue using CSB-PA320739LA01HU at dilution of 1:100

  • Immunohistochemistry of paraffin-embedded human glioma using CSB-PA320739LA01HU at dilution of 1:100

  • Immunofluorescence staining of HepG2 cells with CSB-PA320739LA01HU at 1:166, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) HLA-C Polyclonal antibody
Uniprot No.
Target Names
HLA-C
Alternative Names
1C07_HUMAN antibody; Cw-7 alpha chain antibody; D6S204 antibody; HLA class I histocompatibility antigen antibody; HLA class I histocompatibility antigen; C alpha chain antibody; HLA class I histocompatibility antigen; Cw-1 alpha chain antibody; HLA JY3 antibody; HLA-C antibody; HLA-C histocompatibility type antibody; HLA-Cw antibody; HLA-JY3 antibody; HLAC antibody; HLC C antibody; HLC-C antibody; human leukocyte antigen-C alpha chain antibody; major histocompatibility antigen HLA-C antibody; major histocompatibility complex; class I; C antibody; MHC class I antigen antibody; MHC class I antigen Cw 1 antibody; MHC class I antigen Cw*7 antibody; MHC class I antigen heavy chain HLA-C antibody; PSORS1 antibody
Raised in
Rabbit
Species Reactivity
Human, Mouse
Immunogen
Recombinant Human HLA class I histocompatibility antigen, Cw-7 alpha chain protein (62-306AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated

The HLA-C Antibody (Product code: CSB-PA320739LA01HU) is Non-conjugated. For HLA-C Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA320739LB01HU HLA-C Antibody, HRP conjugated ELISA
FITC CSB-PA320739LC01HU HLA-C Antibody, FITC conjugated
Biotin CSB-PA320739LD01HU HLA-C Antibody, Biotin conjugated ELISA
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Tested Applications
ELISA, WB, IHC, IF
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:5000
IHC 1:20-1:200
IF 1:50-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Description

The HLA-C antibody can be used to recognize the human and mouse HLA-C protein. A rabbit got immunization with the recombinant human HLA class I histocompatibility antigen, Cw-7 alpha chain protein (62-306aa). After that, an immune response occurred in the rabbit producing large amounts of antibodies against the HLA-C protein. The rabbit's blood was collected and isolated to get the anti-serum, which was protein G-purified to obtain the HLA-C polyclonal antibody (purity 95%+). This HLA-C antibody has accessed its specificity in ELISA, WB, IHC, and IF applications.

The HLA class I histocompatibility antigen, Cw-7 alpha chain protein mainly functions to present peptides derived from intracellular proteins to CD8+ T cells for immune recognition, helping to regulate the immune response and protect the body against infected or abnormal cells.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Antigen-presenting major histocompatibility complex class I (MHCI) molecule with an important role in reproduction and antiviral immunity. In complex with B2M/beta 2 microglobulin displays a restricted repertoire of self and viral peptides and acts as a dominant ligand for inhibitory and activating killer immunoglobulin receptors (KIRs) expressed on NK cells. In an allogeneic setting, such as during pregnancy, mediates interaction of extravillous trophoblasts with KIR on uterine NK cells and regulate trophoblast invasion necessary for placentation and overall fetal growth. During viral infection, may present viral peptides with low affinity for KIRs, impeding KIR-mediated inhibition through peptide antagonism and favoring lysis of infected cells. Presents a restricted repertoire of viral peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-C-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected cells, particularly in chronic viral infection settings such as HIV-1 or CMV infection. Both the peptide and the MHC molecule are recognized by TCR, the peptide is responsible for the fine specificity of antigen recognition and MHC residues account for the MHC restriction of T cells. Typically presents intracellular peptide antigens of 9 amino acids that arise from cytosolic proteolysis via proteasome. Can bind different peptides containing allele-specific binding motifs, which are mainly defined by anchor residues at position 2 and 9. Preferentially displays peptides having a restricted repertoire of hydrophobic or aromatic amino acids (Phe, Ile, Leu, Met, Val and Tyr) at the C-terminal anchor.; ALLELE C*01:02: The peptide-bound form interacts with KIR2DL2 and KIR2DL3 inhibitory receptors on NK cells. The low affinity peptides compete with the high affinity peptides impeding KIR-mediated inhibition and favoring lysis of infected cells. Presents to CD8-positive T cells a CMV epitope derived from UL83/pp65 (RCPEMISVL), an immediate-early antigen necessary for initiating viral replication.; ALLELE C*04:01: Presents a conserved HIV-1 epitope derived from env (SFNCGGEFF) to memory CD8-positive T cells, eliciting very strong IFNG responses. Presents CMV epitope derived from UL83/pp65 (QYDPVAALF) to CD8-positive T cells, triggering T cell cytotoxic response.; ALLELE C*05:01: Presents HIV-1 epitope derived from rev (SAEPVPLQL) to CD8-positive T cells, triggering T cell cytotoxic response.; ALLELE C*06:02: In trophoblasts, interacts with KIR2DS2 on uterine NK cells and triggers NK cell activation, including secretion of cytokines such as GMCSF that enhances trophoblast migration.; ALLELE C*07:02: Plays an important role in the control of chronic CMV infection. Presents immunodominant CMV epitopes derived from IE1 (LSEFCRVL and CRVLCCYVL) and UL28 (FRCPRRFCF), both antigens synthesized during immediate-early period of viral replication. Elicits a strong anti-viral CD8-positive T cell immune response that increases markedly with age.; ALLELE C*08:01: Presents viral epitopes derived from CMV UL83 (VVCAHELVC) and IAV M1 (GILGFVFTL), triggering CD8-positive T cell cytotoxic response.; ALLELE C*12:02: Presents CMV epitope derived from UL83 (VAFTSHEHF) to CD8-positive T cells.; ALLELE C*15:02: Presents CMV epitope derived from UL83 CC (VVCAHELVC) to CD8-positive T cells, triggering T cell cytotoxic response.
Gene References into Functions
  1. This study suggests that polytransfused patients with SCA possessing the HLA-DQB1*03 and HLA-C*06 allele variants are more susceptible to alloimmunisation. In addition, HLA-DRB1*04 and HLA-DRB1*11 alleles were seen to be associated with the production of anti-Fy(a) and anti-K antibodies, respectively. PMID: 28881103
  2. Binding stability to beta2-microglobulin may confer to HLA-C the ability to preferentially act either as a conventional immune-competent molecule or as an accessory molecule involved in HIV-1 infectivity via viral envelope glycoprotein binding. PMID: 28051183
  3. the results show that HLA-C incompatibility between couples is significantly associated with unexplained recurrent miscarriage PMID: 29205643
  4. this study shows that HLA-C genetic variance is associated with HIV-1 viral load in seroconverters from Zambia and Rwanda PMID: 29289742
  5. this study shows that HLA-C1 ligands are associated with increased susceptibility to systemic lupus erythematosus PMID: 29395276
  6. this study demonstrates associations of ERAP1 coding variants and domain specific interaction with HLA-C *06 in the early onset psoriasis patients of India PMID: 28867178
  7. Confirmation of the HLA-C*16:97 allele in multiple individuals in Italy, Croatia, Greece, and Turkey has been reported. PMID: 28155256
  8. The results from this large cohort of European patients treated with ustekinumab in daily clinical practice confirm the role of HLA-C*06 as a potential predictor of response to ustekinumab. PMID: 28207934
  9. In silico docking study have confirmed the high binding affinities of multiple 9-mer peptides derived from LL-37 to the HLA-C*06:02 molecule proposed a mechanism of the interaction between this LL-37-HLA-C*06:02 complex and T cells via TCRs. PMID: 27189829
  10. Individuals carrying HLA-C rs9264942 TT genotype showed a significant increased level of HIV-1 viral load pre-treatment, in comparison with individuals carrying the CC genotype (p-value = 0.0092). PMID: 28494720
  11. Human Leukocyte Antigen C*12:02:02 and Killer Immunoglobulin-Like Receptor 2DL5 are Distinctly Associated with Ankylosing Spondylitis in the Taiwanese PMID: 28812990
  12. these study reports an association of the ERAP1 SNP rs30187 with the HLA-C*07 allele in inflammatory bowel disease in the Spanish population PMID: 28651467
  13. The likely HLA class I C*05:142-bearing haplotype is A*02:01~C*05:142~B*44:02. This new allele has a maximum frequency of 0.00001, in 34,743 sequenced-based typed subjects, contrasting with that of C*05:01 (allele frequency 0.10441), in our local, largely UK European, blood donors. PMID: 28639429
  14. In this study, we describe and confirm the distinct expression of HLA-F, HLA-G, HLA-E, and HLA-C in placental tissue PMID: 28185362
  15. childhood acute lymphoblastic leukaemic patients but not healthy controls exhibited B cell populations with very low HLA-C and -E expression levels that could be consistently allocated to the CD19+CD45- leukaemic subset PMID: 26527563
  16. propose that HIV-1 infectivity might depend both on the amounts of HLA-C molecules and on their stability as trimeric complex. According to this model, individuals with low-expression HLA-C alleles and unstable binding to beta2m/peptide might have worse control of HIV-1 infection and an intrinsically higher capacity to support viral replication PMID: 29070683
  17. This study suggests a possible role of killer cell immunoglobulin-like receptors and their ligands in the development of liver damage. The absence of human leucocyte antigen C1 and C2 ligands heterozygosity could lead to less inhibition of natural killer cells and a quicker progression to a high level of fibrosis in patients infected with hepatitis C virus, especially following liver transplantation. PMID: 26717049
  18. KIR2DL2/HLA-C( *)12:02 and KIR2DL2/HLA-C( *)14:03 compound genotypes have protective effects on control of HIV-1. PMID: 27880898
  19. Data establish the C2 allele as a novel genetic risk factor associated with congenital heart block. This observation supports a model in which fetuses with C2 ligand expression and maternal anti-SSA/Ro positivity may have impaired NK cell surveillance, resulting in unchecked cardiac inflammation and scarring. PMID: 29045069
  20. results provide the structural basis for understanding peptide repertoire selection in HLA-C*06:02. PMID: 28855257
  21. Single-nucleotide polymorphisms FOXF1 rs9936833 and MHC rs9257809 remained significantly associated with presence of gastroesophageal acid reflux. The association for risk allele C in FOXF1 rs9936833 and risk allele A in MHC rs9257809 with the presence of acid reflux suggests a potential pathophysiologic mechanism for the role of genetic influences in Barret Esophagus development. PMID: 26822871
  22. The minor alleles of rs2395029, rs9264942, and rs3689068 in the HCP5 and HLA-C, and ZNRD1 genes associate with lower viral loads (VL) among antiretroviral-naive individuals and with shorter time to first VL less 51 copies/ml during anti-HIV therapy. PMID: 27083073
  23. HLA-C*04:01 predisposes to nevirapine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in , but not to other hypersensitivity phenotypes in a sub-Saharan African HIV-infected population PMID: 28062682
  24. Genotyping analysis revealed that HLA-C2, which provides a ligand for killer-cell immunoglobulin-like receptors (KIR) expressed by NK cells, was strongly associated with psoriasis susceptibility. However, no link between the KIR genes themselves and disease was found PMID: 26477484
  25. the signal overall signal that NK cells receive from paternal HLA-C on trophoblasts depends on the ratio of activating and inhibitory KIR genes expressed by them PMID: 27751789
  26. data strengthen our understanding of HLA-C transcriptional regulation and provide a basis for understanding the potential consequences of manipulating HLA-C levels therapeutically PMID: 27817866
  27. KIR2DS2/HLA-C1 may correlate with Hashimoto Thyroiditis pathogenesis. PMID: 27042744
  28. The data suggested the association of IL12B with the psoriasis, however no evidence was observed for the epistatic effect of IL12B with HLA-Cw6 among the psoriasis patients in India. PMID: 27829679
  29. this study first demonstrates hypermethylation of HLA-C gene in psoriatic epidermis, suggesting that HLA-C hypermethylation may be an epigenetic marker in psoriasis. PMID: 27132688
  30. Homozygous HLA-Cw*0602 carriage in plaque psoriasis may predict a favorable outcome after tonsillectomy. The homozygotes more often had psoriasis onset associated with a throat infection and an increased frequency of streptococcal throat infections per lifetime. PMID: 27520394
  31. the combined effect of HLA-Cw6 allele and risk associated genotype near LCE3A gene has a role in psoriasis in the Indian population PMID: 27048876
  32. The absence of KIR-2DS1 in the mother and the presence of HLA-C2 ligand in the child were negatively associated with type 1 diabetes in the child. Our results indicate that maternal KIR genes and their interaction with foetal HLA-C2 may contribute to the risk of type 1 diabetes among Han Chinese children PMID: 26991115
  33. this study shows that in HIV infection, spontaneous controllers express higher levels of HLA-C, along with NK cell activation PMID: 27521484
  34. these results suggest that the HLA-C*06 allele is positively associated with susceptibility to psoriasis, female gender and early onset of psoriasis in South Indian Tamils. PMID: 26796545
  35. gene polymorphism is associated with Crohn's disease in Spanish patients PMID: 26542067
  36. Recurrent Pregnancy Loss in Women with Killer Cell Immunoglobulin-Like Receptor KIR2DS1 is Associated with an Increased HLA-C2 Allelic Frequency PMID: 26589762
  37. genetic polymorphism is associated with the course of Hepatitis C virus infection and the response to therapy PMID: 26206121
  38. HLA-C genetic polymorphism is associated with psoriasis. PMID: 26470763
  39. HLA-C2 and -C1, showed highly significant associations with CRC development. PMID: 26383988
  40. Therefore, the results obtained in this study demonstrate the involvement of HLA class I genes in the susceptibility or resistance to American cutaneous leishmaniasis (ACL), with significant association between HLA-C*04 and ACL susceptibility. PMID: 26600554
  41. HLA-C expressed on HIV-infected cells restricts attack by KIR2DL(+) CD56(dim) natural killer (NK) cells PMID: 26828202
  42. Absence of HLA-C2 for donor KIR2DL1 was associated with higher grade II to IV (HR, 1.4; P = .002) and III to IV acute GVHD (HR, 1.5; P = .01) compared with HLA-C2(+) patients. PMID: 25960307
  43. The authors have identified a deleterious effect of the KIR2DL3-HLA-C1 receptor-ligand combination on HIV clinical outcomes in a Thai cohort. PMID: 26372271
  44. HLA-C -35 C/C allele exerts a favorable effect on the immunological (higher baseline and nadir CD4+ T cell count) and virologic (lower pretreatment HIV viral load) variables. PMID: 26068923
  45. Preformed anti-HLA-Cw and anti-HLA-DP donor specific antibodies have deleterious impact in kidney transplantation. PMID: 26262501
  46. Data suggest regulatory interactions between major histocompatibility antigen HLA-C and killer cell Ig-like receptor (KIR) might promote Graft-versus-Leukemia effects following transplantation. PMID: 26416275
  47. combination of maternal KIR AA with fetal HLA-C2 associated with increased incidence of preeclampsia in Chinese Han population PMID: 24911933
  48. ). In conclusion, we found an interaction between the HLA-Cw6 and LCE genotypes on disease improvement among psoriatic patients treated with anti-TNFs. PMID: 25794162
  49. Possible protective role of human leukocyte antigen Cw7 indicates polyoma BK virus-positive people can be accepted safely for kidney donation. PMID: 25894195
  50. this is the first molecular study of HLA typing in Egyptian patients with vitiligo PMID: 25844609

Show More

Hide All

Subcellular Location
Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass membrane protein.
Protein Families
MHC class I family
Tissue Specificity
Ubiquitous. Highly expressed in fetal extravillous trophoblasts in the decidua basalis (at protein level).
Database Links

HGNC: 4933

OMIM: 142840

KEGG: hsa:3107

STRING: 9606.ENSP00000365402

UniGene: Hs.656020

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 322 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*